Nicotine receptor partial agonists for smoking cessation (Q24235456)

https://api.crossref.org/works/10.1002%2F14651858.CD006103.PUB4

Immediate versus delayed quitting and rates of relapse among smokers treated successfully with varenicline, bupropion SR or placebo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006103.PUB4

Varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs sustained-release bupropion and placebo for smoking cessation: a randomized controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006103.PUB4

Varenicline as maintenance therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006103.PUB4

Quantitative assessment of exposure-response relationships for the efficacy and tolerability of varenicline for smoking cessation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006103.PUB4

Efficacy of varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006103.PUB4

Varenicline treatment for smoking cessation in Asian populations: a pooled analysis of placebo-controlled trials conducted in six Asian countries

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006103.PUB4

Cost-utility analysis of varenicline, an oral smoking-cessation drug, in Japan

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006103.PUB4

Efficacy and tolerability of varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, in a 12-week, randomized, placebo-controlled, dose-response study with 40-week follow-up for smoking cessation in Japanese smokers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006103.PUB4

Varenicline for smoking cessation in patients with coronary heart disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006103.PUB4

Efficacy and safety of varenicline for smoking cessation in patients with cardiovascular disease: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006103.PUB4

Impact of symptoms experienced by varenicline users on tobacco treatment in a real world setting.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006103.PUB4

Mood, side-effects and smoking outcomes among persons with and without probable lifetime depression taking varenicline

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006103.PUB4

Behavioral counseling and varenicline treatment for smoking cessation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006103.PUB4

Smoking-cessation therapy using varenicline: the cost-utility of an additional 12-week course of varenicline for the maintenance of smoking abstinence

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006103.PUB4

Varenicline in prevention of relapse to smoking: effect of quit pattern on response to extended treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006103.PUB4

A longer course of varenicline therapy improves smoking cessation rates.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006103.PUB4

Effect of maintenance therapy with varenicline on smoking cessation: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006103.PUB4

A randomized, placebo-controlled trial of varenicline, a selective alpha4beta2 nicotinic acetylcholine receptor partial agonist, as a new therapy for smoking cessation in Asian smokers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006103.PUB4

A randomized controlled open comparative trial of varenicline vs nicotine patch in adult smokers: efficacy, safety and withdrawal symptoms (the VN-SEESAW study).

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006103.PUB4

Varenicline for smoking cessation: a placebo-controlled, randomized study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006103.PUB4

A double-blind study evaluating the long-term safety of varenicline for smoking cessation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006103.PUB4

Varenicline and bupropion sustained-release combination therapy for smoking cessation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006103.PUB4

Combination treatment with varenicline and nicotine replacement therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006103.PUB4

Pharmacokinetics, safety, and tolerability of varenicline in healthy adolescent smokers: a multicenter, randomized, double-blind, placebo-controlled, parallel-group study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006103.PUB4

Human abuse liability of the smoking cessation drug varenicline in smokers and nonsmokers

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006103.PUB4

Varenicline in the routine treatment of tobacco dependence: a pre-post comparison with nicotine replacement therapy and an evaluation in those with mental illness

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006103.PUB4

An uncontrolled trial of cytisine (Tabex) for smoking cessation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006103.PUB4

Scope and impact of financial conflicts of interest in biomedical research: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006103.PUB4

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006103.PUB4

A preliminary benefit-risk assessment of varenicline in smoking cessation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006103.PUB4

Varenicline: an alpha4beta2 nicotinic receptor partial agonist for smoking cessation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006103.PUB4

Cytisine for smoking cessation: a literature review and a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006103.PUB4

Cytisine for smoking cessation: a research agenda

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006103.PUB4

Neuropharmacology and potential efficacy of new treatments for tobacco dependence

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006103.PUB4

Advances in pharmacotherapy for tobacco dependence.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006103.PUB4

Varenicline: progress in smoking cessation treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006103.PUB4

Bupropion SR as an aid to smoking cessation in smokers treated previously with bupropion: a randomized placebo-controlled study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006103.PUB4

Varenicline and suicidal behaviour: a cohort study based on data from the General Practice Research Database.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006103.PUB4

Efficacy and safety of varenicline for smoking cessation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006103.PUB4

Measuring inconsistency in meta-analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006103.PUB4

Partial agonists as therapeutic agents at neuronal nicotinic acetylcholine receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006103.PUB4

Measures of abstinence in clinical trials: issues and recommendations

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006103.PUB4

Antidepressants for smoking cessation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006103.PUB4

Varenicline: a novel pharmacotherapy for smoking cessation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006103.PUB4

Varenicline: a review of its use as an aid to smoking cessation therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006103.PUB4

Varenicline: a selective alpha4beta2 nicotinic acetylcholine receptor partial agonist approved for smoking cessation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006103.PUB4

Pharmaceutical industry sponsorship and research outcome and quality: systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006103.PUB4

Varenicline is a partial agonist at alpha4beta2 and a full agonist at alpha7 neuronal nicotinic receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006103.PUB4

Use of knock-out mice to determine the molecular basis for the actions of nicotine

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006103.PUB4

Varenicline: new treatment with efficacy in smoking cessation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006103.PUB4

Halogenated cytisine derivatives as agonists at human neuronal nicotinic acetylcholine receptor subtypes

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006103.PUB4

Telephone counselling for smoking cessation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006103.PUB4

Nicotine replacement therapy for smoking cessation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006103.PUB4

Psychiatric adverse events in randomized, double-blind, placebo-controlled clinical trials of varenicline: a pooled analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006103.PUB4

Outcome criteria in smoking cessation trials: proposal for a common standard.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006103.PUB4

Nicotine receptor partial agonists for smoking cessation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006103.PUB4

Nicotine receptor partial agonists for smoking cessation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006103.PUB4

Smoking cessation with varenicline, a selective alpha4beta2 nicotinic receptor partial agonist: results from a 7-week, randomized, placebo- and bupropion-controlled trial with 1-year follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006103.PUB4

7 January 2021

Efficacy and safety of the novel selective nicotinic acetylcholine receptor partial agonist, varenicline, for smoking cessation

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006103.PUB4

7 January 2021

An employer-based cost-benefit analysis of a novel pharmacotherapy agent for smoking cessation

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006103.PUB4

7 January 2021

Pharmacokinetics, safety, and tolerability after single and multiple oral doses of varenicline in elderly smokers

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006103.PUB4

7 January 2021

The efficacy and safety of varenicline for smoking cessation using a flexible dosing strategy in adult smokers: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006103.PUB4

7 January 2021

Comment and reply: A double-blind study evaluating the long-term safety of varenicline for smoking cessation

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006103.PUB4

7 January 2021

Effectiveness of smoking cessation therapies: a systematic review and meta-analysis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006103.PUB4

7 January 2021

Smoking is a disease and smokers are patients

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006103.PUB4

7 January 2021

Preventing 3 million premature deaths and helping 5 million smokers quit: a national action plan for tobacco cessation

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006103.PUB4

7 January 2021